Seth P. Lerner, MD, presented “A Review of The OLYMPUS Trial: Nephron Sparing for UTUC” for the Grand Rounds in Urology audience in October 2019.
How to cite: Lerner, Seth P. “A Review of The OLYMPUS Trial: Nephron Sparing for UTUC” October, 2019. Accessed Oct 2024. https://grandroundsinurology.com/a-review-of-the-olympus-trial-nephron-sparing-for-utuc/
A Review of The OLYMPUS Trial: Nephron Sparing for UTUC -Summary:
Seth P. Lerner, MD, Professor of Urology at Baylor College of Medicine, reviews the results of the Optimized DeLivery of Mitomycin for Primary UTUC Study (OLYMPUS) trial, of which he was the principal investigator. In this study, a thermal, reversible gel was used as a kidney-sparing treatment of low-grade upper tract urothelial cancer (UTUC). He discusses the difficulty of managing UTUC, the function of UGN-101, and the dramatic results in patient outcomes from this trial.
ABOUT THE AUTHOR
Seth P. Lerner, MD, FACS, is Professor of Urology and Vice-Chair for Faculty Affairs in the Scott Department of Urology at the Baylor College of Medicine in Houston, Texas. He holds the Beth and Dave Swalm Chair in Urologic Oncology. Dr. Lerner is the Director of Urologic Oncology and the Multidisciplinary Bladder Cancer Program, also at Baylor.
Dr. Lerner earned his medical degree from the Baylor College of Medicine, completed a surgical internship at Virginia Mason Hospital in Seattle, and returned to Baylor for his residency training. He completed a two-year fellowship at the University of Southern California in Urologic Oncology and Reconstructive Surgery and joined the full-time Baylor faculty in 1992.